Medical cannabis and pediatric patients: state-by-state rules and the evidence base

Pediatric medical cannabis is a different category from adult medical cannabis. The evidence base is narrower (concentrated in pediatric epilepsy syndromes), the regulatory frameworks are more restrictive (most states require additional certifications, caregiver designations, and product-form limits), and the clinical conversation is more cautious (the American Academy of Pediatrics has historically opposed pediatric cannabis use outside of specific severe-disease contexts).

This article walks through the state rules, the FDA-approved indications, the off-label evidence base, and the practical considerations for parents and pediatric clinicians.

What state medical-cannabis programs allow for minors

Most US medical-cannabis states authorize patients under 18 to participate, with three categories of additional structure:

Universal requirement: designated caregiver

In nearly every medical-cannabis state, a minor patient must have a designated adult caregiver (typically a parent or legal guardian) who:

• Registers with the state medical-cannabis program separately.
• Undergoes a criminal-history background check.
• Is the only person authorized to purchase product from licensed dispensaries on the minor's behalf.
• Stores and administers the product (the minor does not handle dispensary transactions directly).

Caregiver age minimums vary: 18 in some states, 21 in others (Pennsylvania, for example, requires caregivers to be 21+ unless the state department of health authorizes a younger caregiver).

Common: two-physician certification for minors

Several states require certifications from two different physicians before approving a minor patient:

• Colorado — minor patients must see two providers at different medical practices each year. For minors diagnosed with a "disabling medical condition" (including PTSD and autism spectrum disorders), the requirement is more flexible than for general qualifying conditions.
• New Hampshire — minor patient applications require diagnosis by two medical providers, one of whom must be a pediatric care provider.
• Connecticut — requires approval from a registered pediatrician in addition to the certifying provider.

The two-physician rule is intended to provide an additional clinical-judgment layer for cases where pediatric cannabis use is being considered.

Common: parental consent documentation

Beyond the caregiver designation, several states require formal parental consent documentation, often notarized, attesting that:

• Both parents (or legal guardians) consent to the medical-cannabis treatment.
• Conventional therapies have been considered or attempted.
• The parents understand the federal Schedule I status (with the narrow April 2026 carve-outs) of cannabis and the implications.

State variation on product forms for minors

Some states impose product-form restrictions specific to minors. The general pattern:

• Smokable flower: generally not authorized for minor patients, even in states where adult patients may obtain it.
• Edibles, tinctures, capsules, oils: typically authorized.
• Vape products / concentrates: state-by-state; some restrict to medical exigency cases.
• Topicals: typically authorized.

The clinical reasoning behind these restrictions: combustion exposes minors to additional pulmonary risk, and high-concentration concentrate products produce difficult-to-titrate dosing in pediatric patients.

The FDA-approved pediatric indication: Epidiolex

The only cannabis-derived medication with an FDA-approved pediatric indication is Epidiolex (cannabidiol oral solution), approved by FDA in 2018 for:

• Lennox-Gastaut syndrome (LGS) in patients 1 year and older.
• Dravet syndrome in patients 1 year and older.
• Tuberous sclerosis complex (TSC) in patients 1 year and older (added by FDA in 2020).

Epidiolex is a cannabidiol-only formulation (≥ 98% CBD by weight, with negligible THC). It is administered as an oral solution at 5–20 mg/kg/day in divided doses, based on clinical response and tolerability.

The pivotal clinical trials that supported FDA approval:

• Lennox-Gastaut syndrome: a phase 3 randomized controlled trial (NEJM 2018) demonstrated a median reduction in atonic ("drop") seizures of 41.9% with 20 mg/kg/day Epidiolex and 37.2% with 10 mg/kg/day, versus 17.2% with placebo, over a 14-week treatment period.
• Dravet syndrome: a phase 3 randomized controlled trial (NEJM 2017) demonstrated a 39% reduction in convulsive seizures with Epidiolex versus 13% with placebo.
• Tuberous sclerosis complex: a phase 3 trial supported the 2020 indication expansion.

Long-term open-label extension data, published through 2024–2025, has shown sustained seizure-reduction efficacy at 36+ months with no new safety signals. The most common adverse effects are somnolence, sedation, lethargy, decreased appetite, and elevated liver-function tests (the last requiring routine LFT monitoring).

For families of children with these specific pediatric epilepsy syndromes, Epidiolex is an FDA-approved prescription drug. It is dispensed through standard pharmacy channels (not through state medical-cannabis dispensaries), is covered by most prescription drug insurance plans, and does not require participation in a state medical-cannabis program.

The off-label / state-program evidence base for other pediatric indications

Beyond Epidiolex's three approved indications, the pediatric evidence base is substantially thinner. The NASEM 2017 consensus report (still the highest-quality systematic review of cannabis evidence) found:

• Strong evidence: chronic-pain management in adults (NASEM does not extend this conclusion to pediatric populations).
• Moderate evidence: short-term sleep improvement in patients with sleep apnea, fibromyalgia, chronic pain, and MS (again, adults).
• Limited evidence: pediatric epilepsy outside the approved syndromes; chemotherapy-induced nausea in cancer treatment; symptoms of Tourette syndrome.
• Insufficient evidence: pediatric autism spectrum disorder, pediatric anxiety, pediatric mental-health conditions generally.

State medical-cannabis programs that authorize pediatric patients for conditions outside Epidiolex's indications are operating on:

• Off-label / outside-FDA-approval clinical judgment.
• Case-series and observational evidence (lower-quality evidence than randomized controlled trials).
• Parental and patient testimony, which is influential in state-program qualifying-condition decisions but does not meet FDA's evidentiary bar.

The conditions most commonly cited for pediatric medical-cannabis program participation outside Epidiolex's indications:

• Other intractable seizure disorders (West syndrome, CDKL5, Aicardi syndrome, etc.).
• Autism spectrum disorder (a small number of states authorize ASD as a qualifying condition; evidence is limited and the AAP has issued cautionary statements).
• Severe / terminal cancer in pediatric patients, primarily for chemotherapy-induced nausea, cachexia, and end-of-life symptom management.
• Severe muscle spasticity in cerebral palsy or related conditions.

Clinical considerations parents should discuss with the pediatric care team

Five concrete clinical considerations:

1. The developing brain. Pediatric brain development continues through the mid-twenties. Cannabis use in adolescence has been associated (in observational studies) with adverse cognitive and mental-health outcomes; the same studies have not been replicated for younger children using state-program medical cannabis under physician supervision, but the underlying concern about CNS development is the basis for the AAP's cautious posture.
2. Drug-drug interactions. Cannabidiol is a known inhibitor of cytochrome P450 enzymes (CYP3A4, CYP2C19) and can elevate serum levels of co-administered anti-seizure medications including clobazam, valproate, and others. Liver-function monitoring is part of the standard Epidiolex protocol; the same monitoring is clinically appropriate for state-program pediatric patients on high-dose CBD products.
3. Product variability. State-program cannabis products are not subject to the same manufacturing and labeling standards as FDA-approved pharmaceuticals. Cannabinoid content can vary from labeled values; contaminants (pesticides, heavy metals, microbial) may be present at levels above what would be acceptable in a pharmacy-dispensed product. Choose state-program operators with rigorous third-party testing and consistent batch documentation.
4. Conventional therapy adequacy. State medical-cannabis programs typically require demonstration that conventional therapies have been attempted, particularly for pediatric patients. This is both a regulatory requirement and a clinical best practice.
5. Ongoing supervision. Pediatric medical-cannabis use is not a "start and forget" therapy. Routine follow-up with both the certifying practitioner and the patient's pediatric care team is appropriate.

What state programs do not solve

Pediatric medical-cannabis program participation does not address several adjacent considerations:

• Custody implications. In some custody disputes, a parent's facilitation of pediatric medical-cannabis use has been cited as a custody concern by the other parent or by child-protective-services investigators. State medical-program participation provides some legal protection in most jurisdictions but does not foreclose these disputes.
• School and daycare administration. Schools and daycare centers operating on federal funds (which is most of them) are generally not authorized to store or administer medical-cannabis products. Some states have passed "Jack's Law" or "Quintin's Law" provisions allowing parents (not school personnel) to administer products on school grounds in specified circumstances; these are state-specific.
• Insurance coverage. With the exception of Epidiolex (covered as a prescription drug for approved indications), pediatric medical-cannabis products are not covered by health insurance.
• Pediatric specialty consultation. Many state-licensed certifying practitioners are not pediatric specialists. For complex pediatric conditions, supplementary consultation with a pediatric neurologist, oncologist, or other appropriate specialist is clinically advisable.

States that are particularly restrictive on pediatric access

A handful of medical-cannabis states make pediatric access more difficult than the typical caregiver-designation framework:

• States with limited / low-THC programs (Georgia, Tennessee, Iowa, Texas TCUP) — pediatric patients can qualify for some conditions but face the same product-form limitations as adult patients (oil-only or low-THC product limits).
• States that authorize medical cannabis but historically excluded minor patients — none currently, but several states (Indiana, others) have no medical-cannabis program at all, making pediatric medical-cannabis access via that state impossible.
• Adult-use-only states without comprehensive medical — Washington and a few others rely primarily on adult-use availability for 21+, leaving pediatric patients in a structurally less-supported framework.

What to ask your state program

For parents considering pediatric medical-cannabis program participation, five questions to verify with your state's specific program:

1. Is my child's condition on the state's qualifying-condition list? For pediatric epilepsy beyond LGS/Dravet/TSC, the answer varies by state.
2. Are two physician certifications required? Colorado and New Hampshire (notably) require two; most other states require one.
3. Must one of the certifying physicians be a pediatric specialist? Connecticut and others require this; most do not.
4. What product forms are authorized for my child's age and condition? Smokable flower is generally not; oils, tinctures, capsules, and other oral forms typically are.
5. What documentation does the state require for caregiver designation? Notarized parental-consent forms, background-check completion, and other items vary by state.

How the schoolday administration question is being addressed

A specific operational question that affects pediatric medical-cannabis families more than any other: how does a child receive their medication during the school day if the medication is medical cannabis?

The structural problem: most US public schools receive federal Title I, school-lunch, or other federal funding that conditions receipt on a drug-free-schools posture. Federal law continues to treat marijuana (outside the narrow April 2026 carve-outs and Epidiolex) as a Schedule III or Schedule I substance that is not authorized for storage or administration on school property by school personnel.

The state-level responses have produced what are colloquially called "Jack's Law" or "Quintin's Law" provisions, named for specific pediatric patient families who advocated for them. These laws typically authorize:

• A designated parent or caregiver (not school personnel) to enter school property to administer medical-cannabis products to the child.
• Administration in a private location designated by the school administration.
• Restrictions on product form (typically oils, tinctures, capsules — not smokable or vaporized products).
• No requirement that the school store the medication.

States with Jack's Law-style provisions include Colorado, Maine, New Jersey, Washington, Illinois, Florida, and Pennsylvania, among others. The implementation varies: some states require advance notification of school administration; others authorize ad-hoc administration. Some schools have been more accommodating than others.

For families navigating this question, the practical starting point is a conversation with the school nurse and the school's special-education or 504-plan coordinator, supported by documentation from the certifying practitioner that explains the medication's role in the child's treatment plan.

What the AAP's posture has been

The American Academy of Pediatrics (AAP) has been historically cautious about pediatric medical-cannabis use outside specific severe-disease contexts. The AAP's 2015 policy statement (which has been the operative document through subsequent updates) makes several points:

• The AAP opposes medical-cannabis use for any condition where alternative therapies with established pediatric safety profiles are available.
• The AAP supports research into cannabis-derived products with rigorous clinical trials.
• The AAP supports compassionate use of pharmaceutical-grade cannabinoid products (e.g., Epidiolex) for severe, life-limiting pediatric conditions where conventional therapy has failed.
• The AAP opposes state-program qualifying-condition expansions that authorize pediatric medical cannabis for conditions with thin clinical evidence (autism spectrum disorder, pediatric anxiety, ADHD).

The AAP's position is influential but not dispositive. State medical-cannabis programs make qualifying-condition decisions through statutory and regulatory processes that consider clinical evidence alongside other factors (patient-advocacy testimony, comparative state-program coverage, legislator preferences). A program that authorizes a condition the AAP cautions against is not violating clinical guidelines per se, but is operating outside the consensus pediatric-medicine framework for that condition.

For parents weighing pediatric medical-cannabis use, the AAP's caution is worth understanding, even where the family ultimately concludes that medical cannabis is appropriate for their child's specific clinical situation.

The pediatric medical-cannabis decision is not equivalent to the adult decision. For families navigating a child's severe condition where conventional therapies have proven inadequate, state programs provide a regulated pathway. The pathway is most evidence-supported for the three FDA-approved Epidiolex indications and weakest for the conditions where state programs and clinical evidence are still catching up to each other.

[Last reviewed 2026-05-18. This is informational only — not medical advice. Pediatric medical-cannabis decisions should be made in consultation with a qualified pediatric clinician and (where applicable) a pediatric subspecialist.]